Lineage Cell Therapeutics Inc (LCTX)

[bobby2loaves]

Ladenburg Thalmann 2018 Healthcare Conference

I just listened to the Ladenburg Thalmann 2018 Healthcare Conference presentation this morning by Russell Skibstead.

He said we'll get initial early data at AOO conference at the end of October. BTX has been not only checking vision, but other functional assessments such as micro-perimetry (light or dark), reading speed, low-light reading and area of goegraphic atophy relative to historic atrophy rate. He said he likes these kinds of results because they are more conclusive than multi-year durg vs placebo type studies. He described the effort as exciting, with BTX in a period where they are "anxiously awaiting data".

I translate all that as BTX will show functional improvement in Cohort 4.

Side note: he also said the AGE distribution will happen in "not too terribly long". I translate that as at least a month.

I guess the marked liked it, or at least didn't hate it. Stock rose from $2.26 to $2.29 in the half hour he spoke.